search
Back to results

Stem Cell Transplant for Bone Marrow Failure Syndromes

Primary Purpose

Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Stem cell transplant
Fludarabine monophosphate
Total lymphoid irradiation
Busulfan
anti-thymocyte globulin
Sponsored by
Masonic Cancer Center, University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diamond-Blackfan Anemia focused on measuring Stem cell transplant, T-cell depletion, TLI, bone marrow failure disorders

Eligibility Criteria

undefined - 35 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients eligible for transplantation under this protocol will be <35 years of age, and will be diagnosed with: a bone marrow failure syndrome unresponsive to available therapy, including but not limited to Diamond-Blackfan anemia, Shwachman Diamond syndrome or Kostmann's neutropenia but exclusive of aplastic anemia. Diamond Blackfan Anemia: Patients must show evidence of steroid resistance requiring equivalent of >6 transfusions yearly despite steroid therapy. Evidence of developing aplasia or myelodysplasia will also be criteria for transplantation. Kostmann's Neutropenia, Shwachman-Diamond syndrome: Patients must have been previously diagnosed as having a clinical picture characteristic of Shwachman-Diamond syndrome (exocrine pancreatic insufficiency, growth retardation, metaphyseal dysostosis, neutropenia), or must have a bone marrow aspirate consistent with Kostmann's neutropenia, with no evidence of acute leukemia. Patients must have failed therapy with granulocyte-colony stimulating factor (G-CSF), as determined by an inability to maintain an absolute neutrophil count (ANC) >750 cells/ml(3), or manifesting recurrent infections despite G-CSF administration resulting in life threatening infections or repeated hospitalizations (<4 /year). Exclusion Criteria: Patients >35 years of age Karnofsky score <70% Hepatic dysfunction as determined by bilirubin >3.0, ALT >150, or active hepatitis Pulmonary function tests with forced volume vital capacity (FVC) and forced expiratory volume (FEV) <70%; O2 saturation <94% Renal dysfunction with glomerular filtration rate (GFR) <30% of predicted. Cardiac compromise, with left ejection fraction <45%. Severe, stable neurologic impairment. Human immunodeficiency virus (HIV) positivity. Pregnant or lactating females

Sites / Locations

  • University of Minnesota Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Bone Marrow Failure Disorders

Arm Description

Patients with Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome

Outcomes

Primary Outcome Measures

Number of Patients Alive (Survival) at 2 Years
Calculated from day 1 of transplant to last contact.

Secondary Outcome Measures

Number of Patients Alive at Three Years (Survival)
Number of subjects who survived 3 years post-transplant.
Number of Patients With Succcessful Engraftment After Transplantation
Number of patients who received non-genotypic identical marrow or cord blood cells using a "non-myeloablative" preparative regimen and exhibited engraftment at Day 42.
Number of Patients With Grade 2-4 Acute Graft Versus Host Disease
Number of patients with Grade 2, 3 and 4 Acute (normally observed within the first 100 days) Graft Versus Host Disease. Acute GVHD is staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of 1 to a high of 4. Patients with grade IV GVHD usually have a poor prognosis. Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening.
Number of Patients With Chronic Graft Versus Host Disease
Number of patients who exhibited chronic (normally occurs after 100 days) Graft Versus Host Disease at 2 years post transplant. Chronic graft-versus-host-disease, over its long-term course, can also cause damage to the connective tissue and exocrine glands.
Number of Patients With Disease Recurrence
Number of patients who exhibited disease recurrence at 2 years.

Full Information

First Posted
September 12, 2005
Last Updated
December 3, 2017
Sponsor
Masonic Cancer Center, University of Minnesota
search

1. Study Identification

Unique Protocol Identification Number
NCT00176878
Brief Title
Stem Cell Transplant for Bone Marrow Failure Syndromes
Official Title
Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
June 2000 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
March 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Masonic Cancer Center, University of Minnesota

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The researchers hypothesize that it will be possible to perform unrelated bone marrow or cord blood transplants in a safer manner by using less intensive therapy yet still achieve an acceptable level of donor cell engraftment for non-malignant congenital bone marrow failure disorders.
Detailed Description
Prior to transplantation, subjects will receive the drugs busulfan (orally or through the catheter), as well as fludarabine and anti-thymocyte globulin (ATG) via the catheter. Busulfan, fludarabine and ATG will be given with Total Lymphoid Irradiation (TLI) to help the new donor bone marrow take and grow after transplantation. Those patients receiving donor marrow will have the T cells (a type of white blood cell in the donor marrow) removed to lower the risk that the new marrow will react to their body, a condition called Graft-Versus-Host-Disease (GVHD). After bone marrow transplantation, subjects will receive drugs to help prevent GVHD, including cyclosporin and mycophenolate mofetil (MMF). Blood samples are taken at day 28, day 60, day 100, 1 year and as required by medical status yearly for five years after transplant to evaluate how well the new marrow is growing. A bone marrow biopsy is required at day 21, at day 100 and 1 year.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
Keywords
Stem cell transplant, T-cell depletion, TLI, bone marrow failure disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bone Marrow Failure Disorders
Arm Type
Experimental
Arm Description
Patients with Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
Intervention Type
Procedure
Intervention Name(s)
Stem cell transplant
Other Intervention Name(s)
BMT
Intervention Description
Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10^9/kg.
Intervention Type
Drug
Intervention Name(s)
Fludarabine monophosphate
Other Intervention Name(s)
Fludara
Intervention Description
fludarabine 175 mg/m^2 (total) on Days -6 through -3.
Intervention Type
Procedure
Intervention Name(s)
Total lymphoid irradiation
Other Intervention Name(s)
TLI
Intervention Description
Dose 500 cGy radiation therapy to specific areas of the body
Intervention Type
Drug
Intervention Name(s)
Busulfan
Other Intervention Name(s)
Busulfex
Intervention Description
Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
Intervention Type
Biological
Intervention Name(s)
anti-thymocyte globulin
Other Intervention Name(s)
ATG
Intervention Description
anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
Primary Outcome Measure Information:
Title
Number of Patients Alive (Survival) at 2 Years
Description
Calculated from day 1 of transplant to last contact.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Number of Patients Alive at Three Years (Survival)
Description
Number of subjects who survived 3 years post-transplant.
Time Frame
3 years
Title
Number of Patients With Succcessful Engraftment After Transplantation
Description
Number of patients who received non-genotypic identical marrow or cord blood cells using a "non-myeloablative" preparative regimen and exhibited engraftment at Day 42.
Time Frame
42 Days
Title
Number of Patients With Grade 2-4 Acute Graft Versus Host Disease
Description
Number of patients with Grade 2, 3 and 4 Acute (normally observed within the first 100 days) Graft Versus Host Disease. Acute GVHD is staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of 1 to a high of 4. Patients with grade IV GVHD usually have a poor prognosis. Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening.
Time Frame
100 Days
Title
Number of Patients With Chronic Graft Versus Host Disease
Description
Number of patients who exhibited chronic (normally occurs after 100 days) Graft Versus Host Disease at 2 years post transplant. Chronic graft-versus-host-disease, over its long-term course, can also cause damage to the connective tissue and exocrine glands.
Time Frame
2 years
Title
Number of Patients With Disease Recurrence
Description
Number of patients who exhibited disease recurrence at 2 years.
Time Frame
2 years

10. Eligibility

Sex
All
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients eligible for transplantation under this protocol will be <35 years of age, and will be diagnosed with: a bone marrow failure syndrome unresponsive to available therapy, including but not limited to Diamond-Blackfan anemia, Shwachman Diamond syndrome or Kostmann's neutropenia but exclusive of aplastic anemia. Diamond Blackfan Anemia: Patients must show evidence of steroid resistance requiring equivalent of >6 transfusions yearly despite steroid therapy. Evidence of developing aplasia or myelodysplasia will also be criteria for transplantation. Kostmann's Neutropenia, Shwachman-Diamond syndrome: Patients must have been previously diagnosed as having a clinical picture characteristic of Shwachman-Diamond syndrome (exocrine pancreatic insufficiency, growth retardation, metaphyseal dysostosis, neutropenia), or must have a bone marrow aspirate consistent with Kostmann's neutropenia, with no evidence of acute leukemia. Patients must have failed therapy with granulocyte-colony stimulating factor (G-CSF), as determined by an inability to maintain an absolute neutrophil count (ANC) >750 cells/ml(3), or manifesting recurrent infections despite G-CSF administration resulting in life threatening infections or repeated hospitalizations (<4 /year). Exclusion Criteria: Patients >35 years of age Karnofsky score <70% Hepatic dysfunction as determined by bilirubin >3.0, ALT >150, or active hepatitis Pulmonary function tests with forced volume vital capacity (FVC) and forced expiratory volume (FEV) <70%; O2 saturation <94% Renal dysfunction with glomerular filtration rate (GFR) <30% of predicted. Cardiac compromise, with left ejection fraction <45%. Severe, stable neurologic impairment. Human immunodeficiency virus (HIV) positivity. Pregnant or lactating females
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul Orchard, MD
Organizational Affiliation
University of Minnesota Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Minnesota Medical Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Stem Cell Transplant for Bone Marrow Failure Syndromes

We'll reach out to this number within 24 hrs